CSL snags a pre­clin­i­cal stem cell ther­a­py in $416M Cal­im­mune buy­out, plans to spin out HIV ef­fort

CSL Behring has bagged the stem cell gene ther­a­py play­er Cal­im­mune for $91 mil­lion and an­oth­er $325 mil­lion in mile­stones for the years-long clin­i­cal jour­ney ahead.

CSL is ac­quir­ing two ther­a­peu­tic tech plat­forms in the deal, which in­volve de­vel­op­ing and de­liv­er­ing stem cell ther­a­pies. CSL’s main pipeline in­ter­est is in Cal­im­mune’s pre­clin­i­cal sick­le cell dis­ease and β-tha­lassemia, which the buy­er sees as a big plus for its work in hema­tol­ogy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER